Find and Pitch Jounalists, Get Your Story Covered

Tags: addiction health addiction | drug development | opioids | Pharmaceuticals | public health | STAT Breakthrough Summit art history drug addiction

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 15 days ago STAT+: Up and down the ladder: The latest comings and goings - about 2 months ago STAT+: Up and down the ladder: The latest comings and goings - about 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Pharmalittle: We’re reading about Trump and tariff worries, PBM rules in New York, and more - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 9 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 11 months ago STAT+: Pharmalittle: We’re reading about a Lilly obesity-drug ad, a $35 cap on inhalers, and more - 11 months ago STAT+: FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers - about 1 year ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - about 1 year ago
2	Mike Hennessy Jr, President and CEO Pharmacy Times Pro middleweight boxer. UK/Ireland. BoxingSports	Key Insights From ASH and SABCS Showcase Advancements for the Field of Oncology Pharmacy - 16 days ago Continuing the Focus on Mental Health - 8 months ago
3	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: With a major patent cliff coming, will JPM play host to some serious deal-making? - 24 days ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 4 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 5 months ago Listen: Live! From the STAT Breakthrough Summit East - 11 months ago
4	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: With a major patent cliff coming, will JPM play host to some serious deal-making? - 24 days ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 4 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 5 months ago STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal - 5 months ago Listen: Live! From the STAT Breakthrough Summit East - 11 months ago STAT Virtual Event \| Cancer’s Breakthrough Engine - about 1 year ago
5	Torie Bosch STAT News Editor at STATNews. Hosts podcast. Pennsylvania opinionspodcasting	Opinion: DEA opioid quotas, women’s health screenings, ADHD as a ‘superpower,’ and more - 28 days ago
6	STAT Staff STAT News Frontiers of health & medicine reporting. healthmedicinejournalism	STAT stories you might have missed in 2024 - about 1 month ago
7	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: 3 trends to watch in biotech in 2025 - about 1 month ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 4 months ago More evidence on GLP-1s and opioid addiction - 4 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 5 months ago
8	Shannon Firth MedPage Today Washington correspondent for MedPageToday. CUNYJschool pride. Healthcarejournalism	Experts Debate the Best Ways to Use Opioid Settlement Funds - about 1 month ago
9	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	3 closely watched drugs that failed in the clinic - about 2 months ago
10	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Oncology, obesity and more: Where pharma R&D is headed in 2025 - about 2 months ago

Journalists covering addiction | drug development | opioids | Pharmaceuticals | public health | STAT Breakthrough Summit